Leah Cann
Stock Analyst at Brookline Capital
(2.14)
# 2,578
Out of 4,818 analysts
16
Total ratings
42.86%
Success rate
8.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Leah Cann
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MEIP MEI Pharma | Maintains: Buy | $80 | $1.98 | +3,940.40% | 2 | May 23, 2023 | |
| CRBU Caribou Biosciences | Initiates: Buy | $19 | $0.84 | +2,149.32% | 1 | Feb 14, 2022 | |
| CCCC C4 Therapeutics | Initiates: Buy | $54 | $1.63 | +3,223.08% | 1 | Jun 24, 2021 | |
| AGIO Agios Pharmaceuticals | Assumes: Perform | n/a | $28.43 | - | 4 | Feb 20, 2019 | |
| EXEL Exelixis | Upgrades: Outperform | n/a | $36.78 | - | 2 | Feb 27, 2018 | |
| NTLA Intellia Therapeutics | Initiates: Perform | n/a | $8.10 | - | 1 | Jul 18, 2017 | |
| EDIT Editas Medicine | Initiates: Perform | n/a | $1.56 | - | 1 | Jul 18, 2017 | |
| CRSP CRISPR Therapeutics AG | Initiates: Perform | n/a | $38.60 | - | 1 | Jul 18, 2017 | |
| VSTM Verastem | Initiates: Outperform | $72 | $7.18 | +902.79% | 3 | Apr 13, 2017 |
MEI Pharma
May 23, 2023
Maintains: Buy
Price Target: $80
Current: $1.98
Upside: +3,940.40%
Caribou Biosciences
Feb 14, 2022
Initiates: Buy
Price Target: $19
Current: $0.84
Upside: +2,149.32%
C4 Therapeutics
Jun 24, 2021
Initiates: Buy
Price Target: $54
Current: $1.63
Upside: +3,223.08%
Agios Pharmaceuticals
Feb 20, 2019
Assumes: Perform
Price Target: n/a
Current: $28.43
Upside: -
Exelixis
Feb 27, 2018
Upgrades: Outperform
Price Target: n/a
Current: $36.78
Upside: -
Intellia Therapeutics
Jul 18, 2017
Initiates: Perform
Price Target: n/a
Current: $8.10
Upside: -
Editas Medicine
Jul 18, 2017
Initiates: Perform
Price Target: n/a
Current: $1.56
Upside: -
CRISPR Therapeutics AG
Jul 18, 2017
Initiates: Perform
Price Target: n/a
Current: $38.60
Upside: -
Verastem
Apr 13, 2017
Initiates: Outperform
Price Target: $72
Current: $7.18
Upside: +902.79%